RECCE PHARMACEUTICALS LTD — AGM Information 2022

Sep 20, 2022

ASX Announcement

Notification of AGM Date

SYDNEY Australia, 21 September 2022: Recce Pharmaceuticals Ltd ( ASX:RCE , FSE:R9Q ) (the Company ), advises that its Annual General Meeting will be held at 2.00pm (Sydney time) on Monday, 14 November 2022, further details of which will be provided in the notice of meeting to be dispatched to shareholders in due course.

In accordance with Listing Rule 3.13, the Company advises that the closing date for the receipt of director nominations is 30 September 2022.

This announcement has been approved for release by the Chairman of the Company.

For further information, please contact:

James Graham – Chief Executive Officer, +61 2 9256 2571 Maggie Niewidok – Company Secretary, +61 2 8072 1400

==> picture [533 x 61] intentionally omitted <==

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE , FSE: R9Q ) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE[® ] 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE[®] 435 as an orally administered therapy for bacterial infections; and RECCE[®] 529 for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

The FDA has awarded RECCE[® ] 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE[® ] 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. RECCE[®] 327 is not yet market approved for use in humans with further clinical testing required to fully evaluate safety and efficacy.

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s antiinfective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.

==> picture [559 x 76] intentionally omitted <==